Réza‐Thierry Elaidi

Prostate-specific antigen flare induced by cabazitaxel-based chemotherapy in patients with metastatic castration-resistant prostate cancer

Antoine Angelergues, Denis Maillet, Aude Fléchon et al. · European Journal of Cancer · 2014 · 53 citations

Urology, Oncology, Genitourinary Cancer +7

Outcomes from second-line therapy in long-term responders to first-line tyrosine kinase inhibitor in clear-cell metastatic renal cell carcinoma

Réza‐Thierry Elaidi, A. Harbaoui, Benoit Beuselinck et al. · Annals of Oncology · 2014 · 28 citations · Full text

Urology, Oncology, Genitourinary Cancer +7

Prognostic factors of survival in patients with metastatic castration resistant prostate cancer (mCRPC) treated with cabazitaxel: Sequencing might matter.

Antoine Angelergues, Denis Maillet, Aude Fléchon et al. · Journal of Clinical Oncology · 2013 · 23 citations

Prognostic Factors, Cancer Management, Pharmacotherapy +19

Duration of response to androgen-deprivation therapy (ADT) and efficacy of secondary hormone therapy, docetaxel (D), and cabazitaxel (C) in metastatic castration-resistant prostate cancer (mCRPC).

Antoine Angelergues, Denis Maillet, Aude Fléchon et al. · Journal of Clinical Oncology · 2014 · 21 citations

Secondary Hormone Therapy, Cancer Management, Pathology +19

mTOR-inhibitor treatment of metastatic renal cell carcinoma: contribution of Choi and modified Choi criteria assessed in 2D or 3D to evaluate tumor response

Michele Lamuraglia, Shahm Raslan, Réza‐Thierry Elaidi et al. · European Radiology · 2015 · 14 citations

Tumor Response, Urology, Oncology +8